Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamotrigine in typical absence epilepsy.

S Buoni1, S Grosso, A Fois

  • 1Institute of Clinical Pediatrics, University of Siena, Italy.

Brain & Development
|July 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epilepsy and coeliac disease in children: a narrative review.

Frontiers in pediatrics·2026
Same author

Recognizing pediatric febrile myoclonus: a video-documented case report and review of the current literature.

Frontiers in pediatrics·2025
Same author

S. aureus bacteremia with acute transverse myelitis case report: Utility of molecular techniques.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2024
Same author

Infections in lung transplanted patients: A review.

Pulmonology·2022
Same author

Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection.

Emerging microbes & infections·2022
Same author

Neridronate for transient osteoporosis of the hip in a child.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022

Lamotrigine effectively controls absence seizures in children, both as add-on therapy for resistant cases and as monotherapy for newly diagnosed typical absence seizures. This anti-epileptic drug shows promise for managing difficult-to-treat epilepsy.

Area of Science:

  • Neurology
  • Pediatric Epilepsy
  • Pharmacology

Background:

  • Absence seizures, including childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), can be challenging to treat.
  • Lamotrigine (LTG) is an established anti-epileptic drug with emerging evidence for its efficacy in specific pediatric epilepsy syndromes.

Purpose of the Study:

  • To evaluate the effectiveness of lamotrigine (LTG) in pediatric patients with absence seizures.
  • To assess LTG as both an add-on therapy for treatment-resistant cases and as monotherapy for newly diagnosed typical absence seizures.

Main Methods:

  • Patients were diagnosed using strict criteria and divided into two groups: treatment-resistant absence seizures (n=8) receiving LTG add-on therapy, and newly diagnosed typical absence seizures (n=7) receiving LTG monotherapy.

Related Experiment Videos

  • Seizure control, drug withdrawal, and adverse events were monitored.

    • Main Results:

    • Full seizure control was achieved in all patients with treatment-resistant absence seizures on LTG add-on therapy.
    • Five of these patients were successfully transitioned to LTG monotherapy after a mean of 12.5 months.
    • Six of seven patients receiving LTG monotherapy for typical absence seizures achieved full seizure control; one discontinued due to rash.

    Conclusions:

    • Lamotrigine is effective for managing treatment-resistant absence seizures, particularly when used in combination with valproic acid.
    • Preliminary findings suggest lamotrigine monotherapy is a viable option for typical absence seizures, though potential side effects like skin rash should be considered.